



## **LOBE SCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON APRIL 14, 2021**

**Lobe invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference**

April 12, 2021 Vancouver, British Columbia – Lobe Sciences Ltd. ("**Lobe**" or the "**Company**") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce that it has been invited to present at the Emerging Growth Conference on April 14, 2021.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and Director, Philip Young in real time.

Lobe will be presenting at 10:30 am Eastern time for 45 minutes. Mr. Young will provide a full presentation and will be available for questions after his presentation.

Interested participants are encouraged to register in advance at:  
[https://goto.webcasts.com/starthere.jsp?ei=1451311&tp\\_key=5b36cea9ad&sti=lobe](https://goto.webcasts.com/starthere.jsp?ei=1451311&tp_key=5b36cea9ad&sti=lobe)

An archived webcast will also be made available on [EmergingGrowth.com](https://www.emerginggrowth.com) after the live event.

### **About the Emerging Growth Conference**

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

### **About Lobe Sciences Ltd.**

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using

psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

**For further information please contact:**

**Lobe Sciences Ltd.**

Philip J Young, CEO

info@lobesciences.com

Tel: (949) 505-5623

*THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.*

***Disclaimer for Forward Looking Statements***

*This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the development of innovative devices and delivery mechanisms to improve mental health and wellness are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at [www.sedar.com](http://www.sedar.com). As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.*